The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of neural transmission

• Publication date

  2007-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00702-006-0499-1PMID 16736232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice

  2005cited by this paper
• Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

  2005cited by this paper
• Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain

  2005cited by this paper
• Wilson's Disease: Clinical, Genetic and Pharmacological Findings

  2005cited by this paper
• Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

  2005cited by this paper
• Neurologically Presenting Wilson’s Disease

  2005cited by this paper
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

  2005influential reference
• Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28

  2004cited by this paper
• Iron, brain ageing and neurodegenerative disorders

  2004cited by this paper
• Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.

  2004cited by this paper
• Neuroprotective Effect of Acute and Chronic Administration of Copper (II) Sulfate against MPP+ Neurotoxicity in Mice

  2004cited by this paper
• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  2003cited by this paper
• The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia.

  2002cited by this paper
• Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.

  2002cited by this paper
• Glutathione, iron and Parkinson's disease.

  2002cited by this paper
• Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.

  2001cited by this paper
• Effects of R‐ and S‐apomorphine on MPTP‐induced nigro‐striatal dopamine neuronal loss

  2001cited by this paper
• Brain iron pathways and their relevance to Parkinson's disease.

  2001cited by this paper
• Role of Free Radicals in the Neurodegenerative Diseases

  2001cited by this paper
• Nitric oxide mediated modulation of norepinephrine transport: identification of a potential target for S‐nitrosylation

  2000cited by this paper
• Oxidative Stress, Mitochondrial Respiration, and Parkinson's Disease

  2000cited by this paper
• The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease.

  2000cited by this paper
• Apomorphine protects against MPTP‐induced neurotoxicity in mice

  1999cited by this paper
• Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐Hydroxydopamine

  1998cited by this paper
• The effects of iron loading and iron deficiency on the tissue uptake of 64Cu during development in the rat.

  1996cited by this paper
• Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

  1996cited by this paper
• Oxidative stress and the pathogenesis of Parkinson's disease

  1996cited by this paper
• Melatonin is protective against MPTP-induced striatal and hippocampal lesions.

  1996cited by this paper
• Depletion of copper and manganese in brain after MPTP treatment of mice.

  1995influential reference
• Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis

  1994influential reference
• Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.

  1994cited by this paper
• Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

  1994cited by this paper
• Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?

  1994cited by this paper
• Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study.

  1994cited by this paper
• The possible role of iron in the etiopathology of parkinson's disease

  1993cited by this paper
• MRI, brain iron and experimental Parkinson's disease.

  1992cited by this paper
• Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis

  1992cited by this paper
• The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons

  1991cited by this paper
• Brain iron and ferritin in Parkinson's and Alzheimer's diseases

  1990cited by this paper
• Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

  1989cited by this paper
• Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

  1989influential reference
• Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

  1989cited by this paper
• Reduction of Brain Glutathione by l‐Buthionine Sulfoximine Potentiates the Dopamine‐Depleting Action of 6‐Hydroxydopamine in Rat Striatum

  1989cited by this paper
• Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence.

  1989cited by this paper
• Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1987cited by this paper
• Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse.

  1986cited by this paper
• [Fe and Cu content in the liver, spleen, kidney and heart of growing rats with variable Fe and Cu supply].

  1983cited by this paper
• Fe- und Cu-Gehalte in Leber, Milz, Niere und Herz wachsender Ratten bei unterschiedlicher Fe- und Cu-Versorgung

  1983cited by this paper

• Copper, Ceruloplasmin, Zinc, and Manganese Levels in Brain and Biological Fluids from Parkinson’s Disease Patients: Systematic Review and Meta-Analysis

  2026cites this paper
• Combined chronic copper exposure and aging lead to neurotoxicity in vivo.

  2023cites this paper
• Unscrambling the Role of Redox-Active Biometals in Dopaminergic Neuronal Death and Promising Metal Chelation-Based Therapy for Parkinson’s Disease

  2023cites this paper
• Neurotoxicity of copper and copper nanoparticles

  2021cites this paper
• Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?

  2020cites this paper
• Iron overload resulting from the chronic oral administration of ferric citrate induces parkinsonism phenotypes in middle-aged mice

  2019cites this paper
• Neurotoxicity of Copper.

  2017cites this paper
• Potential Beneficial Effects of Bilirubin Together with D-Penicillamine in the Treatment of Chronic Neurodegenerative Diseases

  2017cites this paper
• Iron and Parkinson's disease.

  2015influential citation
• The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof.

  2015cites this paper
• Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.

  2015cites this paper
• Copper and Copper Proteins in Parkinson's Disease

  2014cites this paper
• Redox Status and Aging Link in Neurodegenerative Diseases

  2014cites this paper
• Metabolism and functions of copper in brain.

  2014cites this paper
• Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration

  2013cites this paper
• Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

  2013cites this paper
• Copper in Brain and Neurodegeneration

  2013cites this paper
• Rapid Copper Acquisition by Developing Murine Mesothelioma: Decreasing Bioavailable Copper Slows Tumor Growth, Normalizes Vessels and Promotes T Cell Infiltration

  2013cites this paper
• Copper: effects of deficiency and overload.

  2013cites this paper
• The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases

  2012cites this paper
• Treatment of Cystic Fibrosis with Penicillamine. A Hypothesis Based on the Physiology of Mucus and Sweat

  2012cites this paper
• Copper metabolism and copper-mediated alterations in the metabolism of cultured astrocytes

  2012cites this paper
• PET Imaging a MPTP-Induced Mouse Model of Parkinson’s Disease Using the Fluoropropyl-Dihydrotetrabenazine Analog [18F]-DTBZ (AV-133)

  2012cites this paper
• Chelators in the Treatment of Iron Accumulation in Parkinson's Disease

  2012cites this paper
• The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease

  2011cites this paper
• Iron chelation and neuroprotection in neurodegenerative diseases

  2011cites this paper
• The transition metals copper and iron in neurodegenerative diseases.

  2010cites this paper
• Role of iron in neurotoxicity: a cause for concern in the elderly?

  2009cites this paper
• Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30

  2009cites this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cites this paper